CANbridge Pharmaceuticals Inc. (HKG:1228)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 1.14B -18.9% |
| Revenue (ttm) | 64.28M -11.0% |
| Net Income | -94.11M |
| EPS | -0.18 |
| Shares Out | 597.44M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 83,000 |
| Open | 1.895 |
| Previous Close | 1.890 |
| Day's Range | 1.885 - 1.925 |
| 52-Week Range | 1.610 - 3.500 |
| Beta | -0.16 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 28, 2026 |
About CANbridge Pharmaceuticals
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy (ERT) for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible ileal bile acid transporter inhibitor for the treatment of alagille syndrome and progressive familial intrahepatic cholestasis. It also develops CAN106, an anti-C5 mAb for paroxysmal nocturnal hemoglobinu... [Read more]
News
CANbridge Posts H1 Loss Despite Higher Revenue; Stock Down
(RTTNews) - CANbridge Pharmaceuticals Inc. (1228.HK) reported interim financial results for the first half ended June 30, 2026. The company incurred a loss for the period, compared to a profit last ye...
CANbridge Pharmaceuticals Earnings release: H1 2026
CANbridge Pharmaceuticals released its H1 2026 earnings on August 28, 2026, summarizing the period's financial results.
CANbridge Pharmaceuticals Quarterly report: H1 2026
CANbridge Pharmaceuticals has published its H1 2026 quarterly earnings report on August 28, 2026.
CANbridge Pharmaceuticals Earnings release: H2 2025
CANbridge Pharmaceuticals released its H2 2025 earnings on March 30, 2026, summarizing the period's financial results.
CANbridge Pharmaceuticals Annual report: H2 2025
CANbridge Pharmaceuticals has published its H2 2025 annual report on March 30, 2026.
China's Push To Expand Access To Costly Therapies And A Partnership Deal Boost Rare Drugs Maker - But Is It Enough?
The maker of drugs for rare diseases has enjoyed an explosive rise in its share price, helped by a partnership deal and Chinese moves to widen access to costly therapies Key Takeaways： A drug distribu...